Farmacoterapia para dejar de fumar
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Fiore Mc, Jaén cr, Baker tB, et al. treating tobacco use and dependence: 2008 update [i nternet]. rockville, Md: u.s . department of Health and Human services. Public Health service; 2008 May. 257 p [citado: 18/06/2010]. (c linical Practice Guideline). disponible en: www.surgeongeneral.gov/tobacco/treating_tobacco_use.pdf
chapman s, MacKenzie r. the global research neglect of unassisted smoking cessation: causes and consequences. Plos Med. 2010;7(2):e1000216. DOI: https://doi.org/10.1371/journal.pmed.1000216
etter JF, Huguelet P, Perneger tv, et al. nicotine gum treatment before smoking cessation: a randomized trial. arch intern Med. 2009;169(11):1028-34 DOI: https://doi.org/10.1001/archinternmed.2009.12
Hurt rd, sachs dP, Glover ed, et al. a comparison of sustained-release bupropion and placebo for smoking cessation. n e ngl J Med. 1997;337(17):1195-202 DOI: https://doi.org/10.1056/NEJM199710233371703
Bjornsson td, callaghan Jt, einolf HJ, et al. the conduct of in vitro and in vivo drug-drug interaction studies: a PhrMa perspective. J clin Pharmacol. 2003;43(5):443-69. DOI: https://doi.org/10.1177/0091270003043005001
Paulzen M, clement HW, Gründer G. enhancement of atomoxetine serum levels by co-administration of paroxetine. int Jneuropsychopharmacol. 2008; 11(2):289-91. DOI: https://doi.org/10.1017/S1461145707008115
lefebvre J, Poirier l, Poirier P, et al. the influence of cYP2d6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J clin Pharmacol. 2007; 63(5):575-82. DOI: https://doi.org/10.1111/j.1365-2125.2006.02796.x
Goetz MP, Knox sK, suman vJ, et al. the impact of cytochrome P450 2d6 metabolism in women receiving adjuvant tamoxifen. Breast cancer res treat. 2007; 101(1):113-21 DOI: https://doi.org/10.1007/s10549-006-9428-0
Medwath. Fda safety information and adverse event reporting program. Wellbutrin (bupropion hydrochloride) tablets and sustained-release tablets [internet]. silver spring, Md: Fda; 2009 [citado: 23/03/2010]. disponible en: http://www.fda.gov/safety/MedWatch/safetyinformation/ucm176817.htm
Jorenby de, Hays Jt, rigotti na, et al. efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J aMa . 2006;296(1):56-63. errata en: JaMa. 2006; 296(11):1355. DOI: https://doi.org/10.1001/jama.296.1.56
Moore tJ. strong safety signal seen for new varenicline risks [internet]. Horsham, Pa: institute for safe Medication Practices; 2008 May [citado: 23/03/2010]. disponible en: www.ismp.org/quarterwatch/chantixreport.asp.
Medwath. Fda safety information and adverse event reporting program. chantix (varenicline) 0.5 mg and 1 mg tablets [internet]. silver spring, Md: Fda; 2009 [citado: 23/03/2010]. disponible en: http://www.fda.gov/safety/MedWatch/safetyinformation/ucm175783.htm
the smoking cessation aids varenicline (marketed as chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. Fda drug safety newsletter [i nternet]. 2009;2(1):1-4 [citado: 23/03/2010]. disponible en: http://www.fda.gov/downloads/drugs/drugs afety/drugs afetynewsletter/ucm107318.pdf.
Kuehn BM. studies linking smoking-cessation drug with suicide risk spark concerns. JaMa. 2009;301(10):1007-8. DOI: https://doi.org/10.1001/jama.2009.293
u.s . Preventive services task Force. counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: u.s . Preventive services task Force reaffirmation recommendation statement. ann intern Med. 2009;150(8):551-5. DOI: https://doi.org/10.7326/0003-4819-150-8-200904210-00009
Bruin Je, Gerstein Hc, Holloway ac. long-term consequences of fetal and neonatal nicotine exposure: a critical review. toxicol sci. 2010;116(2):364-74. DOI: https://doi.org/10.1093/toxsci/kfq103
coleman t, Britton J, thornton J. nicotine replacement therapy in pregnancy. BMJ. 2004;328(7446):965-6. DOI: https://doi.org/10.1136/bmj.328.7446.965
Grimshaw GM, stanton a. tobacco cessation interventions for young people. cochrane database syst rev. 2006;(4): cd003289. DOI: https://doi.org/10.1002/14651858.CD003289.pub4
Mc robbie H, Hajek P. nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. addiction. 2001;96(11):1547-51 DOI: https://doi.org/10.1046/j.1360-0443.2001.961115472.x
Meine tJ, Patel Mr, Washam JB, et al. safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. am J cardiol. 2005;95(8):976-8. DOI: https://doi.org/10.1016/j.amjcard.2004.12.039
Hubbard r, lewis s, smith c, et al. use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. tob control. 2005;14(6):416-21 DOI: https://doi.org/10.1136/tc.2005.011387
Mohiuddin sM, Mooss an, Hunter cB, et al. intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. chest. 2007;131(2):446-52. DOI: https://doi.org/10.1378/chest.06-1587
rigotti na, thorndike an, regan s, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. am J Med. 2006;119(12):1080-7. DOI: https://doi.org/10.1016/j.amjmed.2006.04.024
rigotti na, Pipe al, Benowitz nl, et al. efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. circulation. 2010;121(2):221-9. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.869008